Copanlisib (BioDeep_00000858742)
代谢物信息卡片
化学式: C23H28N8O4 (480.2233408)
中文名称: 库潘尼西
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5
InChI: InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EM - Phosphatidylinositol-3-kinase (pi3k) inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:173077
- KEGGdrug: D10867
- PubChem: 135565596
- DrugBank: DB12483
- ChEMBL: CHEMBL3218576
- CAS: 1032568-63-0
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Harsha K Tripathy, S V Nair Manju, Rama Murthy Bestha, Vinay Kiran, Sreekanth Dittakavi, Ramesh Mullangi. Validated liquid chromatography-tandem mass spectrometry method for simultaneous quantitation of bendamustine and copanlisib in mouse plasma: Application to a pharmacokinetic study in mice.
Biomedical chromatography : BMC.
2022 Aug; 36(8):e5387. doi:
10.1002/bmc.5387. [PMID: 35470912] - Weiping Liu, Lingyan Ping, Yan Xie, Yingli Sun, Tingting Du, Yi Niu, Galia Cisternas, Funan Huang, Jose Garcia-Vargas, Barrett H Childs, Aruna Mehra, Susanne Reschke, Xiaopei Wang, Yuqin Song, Jun Zhu. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
Cancer chemotherapy and pharmacology.
2022 Jun; 89(6):825-831. doi:
10.1007/s00280-022-04417-3. [PMID: 35322287] - Shin Morioka, Hiroki Nakanishi, Toshiyoshi Yamamoto, Junya Hasegawa, Emi Tokuda, Tomoya Hikita, Tomoko Sakihara, Yuuki Kugii, Chitose Oneyama, Masakazu Yamazaki, Akira Suzuki, Junko Sasaki, Takehiko Sasaki. A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their disease-associated regulation.
Nature communications.
2022 01; 13(1):83. doi:
10.1038/s41467-021-27648-z. [PMID: 35013169] - Anup Siddesh, Dhurvu Sriram, Ashok Zakkula, Rajnish Kumar, Sreekanth Dittakavi, Mohd Zainuddin, Ravi Kumar Trivedi, Ramesh Mullangi. Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Biomedical chromatography : BMC.
2021 Apr; 35(4):e5015. doi:
10.1002/bmc.5015. [PMID: 33125719] - Paul Dent, Laurence Booth, Andrew Poklepovic, Daniel Von Hoff, John F Hancock. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
Cellular signalling.
2020 04; 68(?):109525. doi:
10.1016/j.cellsig.2020.109525. [PMID: 31911180] - Ya'nan Yu, Yuqiao Han, Fupo Zhang, Zhenmei Gao, Tong Zhu, Suzhen Dong, Mingliang Ma. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.
Journal of medicinal chemistry.
2020 03; 63(6):3028-3046. doi:
10.1021/acs.jmedchem.9b01736. [PMID: 32069401] - Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey, Simon A J Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, Li Liu, Karl Köchert, Kui Shen, Christoph Kneip, Carol E Peña, Joachim Grevel, Jun Zhang, Galia Cisternas, Susanne Reschke, Camille Granvil, Ahmad Awada. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Molecular cancer therapeutics.
2020 02; 19(2):468-478. doi:
10.1158/1535-7163.mct-19-0466. [PMID: 31619463] - Anshul Kumar, Rohit Bhatia, Pooja Chawla, Durgadas Anghore, Vipin Saini, Ravindra K Rawal. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Anti-cancer agents in medicinal chemistry.
2020; 20(10):1158-1172. doi:
10.2174/1871520620666200317105207. [PMID: 32183683] - Aimie E Garces, Michael J Stocks. Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective.
Journal of medicinal chemistry.
2019 05; 62(10):4815-4850. doi:
10.1021/acs.jmedchem.8b01492. [PMID: 30582807] - Sreekanth Dittakavi, Ramesh Mullangi. LC-ESI-MS/MS determination of copanlisib, a novel PI3K inhibitor, in mouse plasma and its application to a pharmacokinetic study in mice.
Biomedical chromatography : BMC.
2019 Apr; 33(4):e4460. doi:
10.1002/bmc.4460. [PMID: 30536684] - Seiichi Okabe, Yuko Tanaka, Tetsuzo Tauchi, Kazuma Ohyashiki. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Annals of hematology.
2019 Mar; 98(3):723-733. doi:
10.1007/s00277-018-3547-7. [PMID: 30430191] - Michael Gerisch, Thomas Schwarz, Dieter Lang, Gabriele Rohde, Stefanie Reif, Isabelle Genvresse, Susanne Reschke, Dorina van der Mey, Camille Granvil. Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.
Cancer chemotherapy and pharmacology.
2017 Sep; 80(3):535-544. doi:
10.1007/s00280-017-3383-9. [PMID: 28714036] - Toshihiko Doi, Nozomu Fuse, Takayuki Yoshino, Takashi Kojima, Hideaki Bando, Hideaki Miyamoto, Masato Kaneko, Motonobu Osada, Atsushi Ohtsu. A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Cancer chemotherapy and pharmacology.
2017 Jan; 79(1):89-98. doi:
10.1007/s00280-016-3198-0. [PMID: 27915408] - A Patnaik, L J Appleman, A W Tolcher, K P Papadopoulos, M Beeram, D W Rasco, G J Weiss, J C Sachdev, M Chadha, M Fulk, S Ejadi, J M Mountz, M T Lotze, F G S Toledo, E Chu, M Jeffers, C Peña, C Xia, S Reif, I Genvresse, R K Ramanathan. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology.
2016 10; 27(10):1928-40. doi:
10.1093/annonc/mdw282. [PMID: 27672108] - Ningshu Liu, Bruce R Rowley, Cathy O Bull, Claudia Schneider, Andrea Haegebarth, Christoph A Schatz, Paul R Fracasso, Dean P Wilkie, Martin Hentemann, Scott M Wilhelm, William J Scott, Dominik Mumberg, Karl Ziegelbauer. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Molecular cancer therapeutics.
2013 Nov; 12(11):2319-30. doi:
10.1158/1535-7163.mct-12-0993-t. [PMID: 24170767]